ImmTACTM Platform: Novel bispecific high affinity TCR-effector fusions to modulate the immune system for the treatment of cancer

Date 15 December 2018
Event ESMO Immuno-Oncology Congress 2018
Session Immuno-oncology: State of the art I
Topics Translational Research
Presenter Laure Humbert
Authors L. Humbert
  • Preclinical Biology, Immunocore Ltd, OX14 4RY - Abingdon/GB